We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

131 hedge funds and large institutions have $1.22B invested in Constellation Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 42

2% less funds holding

Funds holding: 134131 (-3)

17% less capital invested

Capital invested by funds: $1.46B → $1.22B (-$244M)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

30% less funds holding in top 10

Funds holding in top 10: 107 (-3)

39% less call options, than puts

Call options by funds: $4.39M | Put options by funds: $7.23M

Holders
131
Holders Change
-3
Holders Change %
-2.24%
% of All Funds
2.3%
Holding in Top 10
7
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-30%
% of All Funds
0.12%
New
14
Increased
49
Reduced
42
Closed
17
Calls
$4.39M
Puts
$7.23M
Net Calls
-$2.83M
Net Calls Change
-$1.77M
Name Holding Trade Value Shares
Change
Change in
Stake
Principal Financial Group
101
Principal Financial Group
Iowa
$247K -$218K -7,191 -41%
VEA
102
Virtus ETF Advisers
New York
$222K +$5.12K +169 +2%
Simplex Trading
103
Simplex Trading
Illinois
$222K +$243K +8,030 +549%
Eagle Capital Management (New York)
104
Eagle Capital Management (New York)
New York
$202K
MLICM
105
Metropolitan Life Insurance Company (MetLife)
New York
$200K
BNP Paribas Financial Markets
106
BNP Paribas Financial Markets
France
$155K +$99.3K +3,278 +98%
Legal & General Group
107
Legal & General Group
United Kingdom
$153K -$9.09K -300 -4%
Royal Bank of Canada
108
Royal Bank of Canada
Ontario, Canada
$130K +$91.5K +3,019 +120%
CAC
109
Cowen and Company
New York
$113K +$146K +4,813 New
CSS
110
Cubist Systematic Strategies
Connecticut
$97K -$442K -14,575 -78%
AA
111
AlphaCentric Advisors
Puerto Rico
$94K
Wells Fargo
112
Wells Fargo
California
$86K -$701K -23,138 -86%
TRCT
113
Tower Research Capital (TRC)
New York
$83K -$57.3K -1,893 -35%
FMT
114
First Mercantile Trust
Tennessee
$69K -$7.82K -258 -8%
T2I
115
Turim 21 Investimentos
Brazil
$63K +$1.36K +45 New
Pacer Advisors
116
Pacer Advisors
Pennsylvania
$61K +$8.36K +276 +12%
AIP
117
Ameritas Investment Partners
Nebraska
$56K
Zurich Cantonal Bank
118
Zurich Cantonal Bank
Switzerland
$51K
Walleye Trading
119
Walleye Trading
New York
$41K +$53K +1,749 New
Canada Life
120
Canada Life
Manitoba, Canada
$33K
PCM
121
Penserra Capital Management
California
$25K -$151 -5 -0.5%
Bank of Montreal
122
Bank of Montreal
Ontario, Canada
$21K -$115K -3,806 -80%
PHK
123
Point72 Hong Kong
Hong Kong
$18K -$26.2K -865 -52%
SFS
124
Sowell Financial Services
Arkansas
$7K -$485 -16 -5%
AWM
125
Accel Wealth Management
Iowa
$6K -$33.3K -1,100 -81%

CNST Hedge Fund Activity: Q1 2021 in Review

131 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q1 2021, worth a combined $1.22B — down 17% from $1.46B a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CNST and 14 opened new positions — a net loss of 3 holders — while 42 trimmed existing stakes and 49 added.

The largest buyer was State Street, adding an estimated $16.3M. The largest seller was Polar Capital Holdings, cutting an estimated $22.7M.

  • 131 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q1 2021, down from 134 in Q4 2020.
  • Funds reported $1.22B of Constellation Pharmaceuticals, Inc. stock for Q1 2021, down 17% quarter-over-quarter.
  • 14 funds opened new Constellation Pharmaceuticals, Inc. positions in Q1 2021 and 17 closed out, a net change of -3 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q1 2021 was State Street, an estimated $16.3M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q1 2021 was Polar Capital Holdings, an estimated $22.7M sold.

Based on aggregated 13F filings for Q1 2021.